Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (3654)	5/2/2001 9:17:24 PM
From: Madharry	Respond to of 52153

I own CEGE again. When I bought it its cash and value of abgx holdings were more than the market cap of the company. So negative valuation on the business seemed cheap enough for me. I also as of today own Maxygen. IPOed last year at 16. the company keeps announcing alliances where they are getting some up front payments and more payments down the road. the latest one a potentially $80MM 3 year deal with a revenue kicker if products are developed.. of the company stock price of $15.25 , $6.62 in cash. It was ipoed by Goldman Sachs and the company was clever enough to do a small follow on offering within a couple of months at much higher prices. The company's focus is on improving molecules mostly industrial enzymes but the last deal was for pharmacutical products I like the fact that the cash on hand seems very in relation to the cash burn. Looks like a quality company with cash and a business model that makes sense, and the price right now seems to be right..

To: Biomaven who wrote (3654)	5/7/2001 11:43:04 AM
From: JOEBT1	Read Replies (1) \| Respond to of 52153

Peter--Re:-CEGE cancer vaccine CEGE's prostrate and pancreatic cancer trials used non patient specific vaccine. In their lung cancer trial they are using patient specific vaccine. I totally agree with you on the difficulties associated with getting approval for patient specific vaccines, however CEGE's goal is to use only non specific vaccines. They have restarted the prostrate cancer trial with a more potent (5 to 10 times) version of their GVAX vaccine. The new version is non specific as was the older GVAX. I've looked at this several times over the years and have decided to "nibble" and maybe "bite" because of upcoming ASCO report. Their cash and ABGX stock value is about 80% of their market value. Joe